AU2021352108B2 - Allosteric akt inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia - Google Patents

Allosteric akt inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia

Info

Publication number
AU2021352108B2
AU2021352108B2 AU2021352108A AU2021352108A AU2021352108B2 AU 2021352108 B2 AU2021352108 B2 AU 2021352108B2 AU 2021352108 A AU2021352108 A AU 2021352108A AU 2021352108 A AU2021352108 A AU 2021352108A AU 2021352108 B2 AU2021352108 B2 AU 2021352108B2
Authority
AU
Australia
Prior art keywords
hht
rule
subject
substitute sheet
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2021352108A
Other languages
English (en)
Other versions
AU2021352108A1 (en
AU2021352108A9 (en
Inventor
Damien PICARD
Pierre Saint-Mezard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vaderis Therapeutics AG
Original Assignee
Vaderis Therapeutics AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaderis Therapeutics AG filed Critical Vaderis Therapeutics AG
Publication of AU2021352108A1 publication Critical patent/AU2021352108A1/en
Publication of AU2021352108A9 publication Critical patent/AU2021352108A9/en
Application granted granted Critical
Publication of AU2021352108B2 publication Critical patent/AU2021352108B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2021352108A 2020-09-30 2021-09-29 Allosteric akt inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia Active AU2021352108B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2015536.2 2020-09-30
GB2015536.2A GB2600384A (en) 2020-09-30 2020-09-30 Allosteric AKT inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia
PCT/EP2021/076811 WO2022069552A1 (en) 2020-09-30 2021-09-29 Allosteric akt inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia

Publications (3)

Publication Number Publication Date
AU2021352108A1 AU2021352108A1 (en) 2023-05-11
AU2021352108A9 AU2021352108A9 (en) 2024-05-23
AU2021352108B2 true AU2021352108B2 (en) 2026-04-02

Family

ID=73197201

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021352108A Active AU2021352108B2 (en) 2020-09-30 2021-09-29 Allosteric akt inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia

Country Status (13)

Country Link
US (1) US12466839B2 (https=)
EP (1) EP4221713A1 (https=)
JP (1) JP2023543993A (https=)
KR (1) KR20230080448A (https=)
CN (1) CN116419924A (https=)
AU (1) AU2021352108B2 (https=)
BR (1) BR112023004885A2 (https=)
CA (1) CA3192433A1 (https=)
CL (1) CL2023000926A1 (https=)
GB (1) GB2600384A (https=)
IL (1) IL301466A (https=)
MX (1) MX2023002996A (https=)
WO (1) WO2022069552A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2600384A (en) 2020-09-30 2022-05-04 Vaderis Therapeutics Ag Allosteric AKT inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia
WO2026038045A1 (en) 2024-08-15 2026-02-19 Almac Discovery Limited Crystalline forms of 6-(4-((1s,3s)-1-amino-3-hydroxycyclobutyl)phenyl)-1-ethyl-7-phenyl-1h-pyrido[2,3-b][1,4]oxazin-2(3h)-one salts and free base

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011077098A1 (en) * 2009-12-23 2011-06-30 Almac Discovery Limited Inhibitors of akt activity

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI301760B (en) 2004-02-27 2008-10-11 Merz Pharma Gmbh & Co Kgaa Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors
US7910561B2 (en) 2004-12-15 2011-03-22 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
EP1898903B8 (en) 2005-06-10 2013-05-15 Merck Sharp & Dohme Corp. Inhibitors of akt activity
WO2008011032A1 (en) 2006-07-17 2008-01-24 Amgen Inc. Quinazoline and pyridopyrimidine derivatives as p38 kinase inhibitors
AR064010A1 (es) 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
JP2010512312A (ja) 2006-12-06 2010-04-22 メルク エンド カムパニー インコーポレーテッド Ａｋｔ活性の阻害剤
US7999107B2 (en) 2007-01-31 2011-08-16 Merck Sharp & Dohme Corp. Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators
JP2011522048A (ja) 2008-06-03 2011-07-28 メルク・シャープ・エンド・ドーム・コーポレイション Ａｋｔ活性の阻害剤
US8536193B2 (en) 2008-06-03 2013-09-17 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
EP2116237A1 (en) 2008-08-05 2009-11-11 Polichem SA Compositions for treating rosacea comprising chitosan and a dicarboxylic acid
EA201101186A1 (ru) 2009-02-13 2012-04-30 Байер Фарма Акциенгезельшафт Конденсированные пиримидины
HUE026323T2 (en) 2011-04-07 2016-05-30 Bayer Ip Gmbh Imidazopyridazines as akt kinase inhibitors
EP3294314A4 (en) 2015-05-15 2019-01-16 Memorial Sloan Kettering Cancer Center USE OF PHOPHOINOSITIDE-3-KINASE INHIBITORS FOR THE TREATMENT OF VASCULAR DISEASES
MX2020002611A (es) 2017-09-07 2020-07-13 Univ Res Inst Inc Augusta Activador especifico de akt3 y usos del mismo.
GB2600384A (en) 2020-09-30 2022-05-04 Vaderis Therapeutics Ag Allosteric AKT inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011077098A1 (en) * 2009-12-23 2011-06-30 Almac Discovery Limited Inhibitors of akt activity

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Ola, R. et al, "SMAD4 Prevents Flow Induced Arteriovenous Malformations by Inhibiting Casein Kinase 2"; Circulation, 138, p.2379-2394 (2018); DOI: 10.1161/CIRCULATIONAHA.118.033842 *
Ola, R. et al.; "OR45 Targeting VEGRF2 signalling rescues arterio-venous malformations in a hemorrhagic human telangiectasia type 2 mouse model "; Angiogenesis, 18, p.525-575 (2015); DOI: 10.1007/s10456-015-9480-7 *

Also Published As

Publication number Publication date
US20240092801A1 (en) 2024-03-21
AU2021352108A1 (en) 2023-05-11
CN116419924A (zh) 2023-07-11
GB2600384A (en) 2022-05-04
WO2022069552A1 (en) 2022-04-07
CL2023000926A1 (es) 2023-11-03
EP4221713A1 (en) 2023-08-09
JP2023543993A (ja) 2023-10-19
MX2023002996A (es) 2023-05-03
KR20230080448A (ko) 2023-06-07
CA3192433A1 (en) 2022-04-07
GB202015536D0 (en) 2020-11-11
US12466839B2 (en) 2025-11-11
BR112023004885A2 (pt) 2023-04-18
IL301466A (en) 2023-05-01
AU2021352108A9 (en) 2024-05-23

Similar Documents

Publication Publication Date Title
CN105308036A (zh) 用于激酶调节的化合物和方法及其适应症
AU2019364631B2 (en) Crystal forms of an ALK2 inhibitor
JP6866381B2 (ja) 化合物
KR20110060901A (ko) Ｎａｄｐｈ 옥시다아제 억제제로서 피라졸로 피리딘 유도체
AU2021352108B2 (en) Allosteric akt inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia
TW201629059A (zh) 二氫吲哚啉酮衍生物
JP6587637B2 (ja) カルボキサミド誘導体
AU2017281980B2 (en) Wnt inhibitors for use in the treatment of fibrosis
CN110325523B (zh) 作为缓激肽b1受体拮抗剂的羧酸芳族酰胺
WO2014060763A1 (en) Compounds useful for treating ocular neovasculan
EP4182311B1 (en) 1-methyl-1h-pyrazol-3-yl derivatives for use in the treatment of neovascular diseases
KR20030016222A (ko) 수술후 스트레스 예방ㆍ치료제
EA049324B1 (ru) Аллостерические ингибиторы akt для применения в лечении наследственной геморрагической телеангиэктазии
CN121079296A (zh) α-v-β-8整合素抑制剂及其用途
HK40074977A (en) Carboxylic acid aromatic amides as antagonists of bradykinin b1 receptor
HK40074982A (en) Carboxylic acid aromatic amides as antagonists of bradykinin b1 receptor
HK40074980A (en) Carboxylic acid aromatic amides as antagonists of bradykinin b1 receptor
WO2015173656A1 (en) Carboxamide derivatives
JPWO2001058489A1 (ja) 術後ストレス予防・治療剤
HK40011855B (en) Carboxylic acid aromatic amides as antagonists of bradykinin b1 receptor
HK40011855A (en) Carboxylic acid aromatic amides as antagonists of bradykinin b1 receptor

Legal Events

Date Code Title Description
SREP Specification republished